TITLE

ALLIFE study: Survivors of ALL had greater insulin resistance prevalence

AUTHOR(S)
Adams, Stacey L.; Haigh, Christen; Harris, Jason
PUB. DATE
August 2009
SOURCE
Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p24
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the findings of two-phase Acute Leukemia Lifestyle Intervention for Everyday (ALLIFE) which investigated insulin resistance and cardiovascular risk in a population of acute lymphoblastic leukemia survivors.
ACCESSION #
43476048

 

Related Articles

  • Resisting insulin resistance.  // Consumer Reports on Health;Jun98, Vol. 10 Issue 6, p6 

    Presents information from a study on insulin resistance which was conducted by researchers at the United States Sports Academy in Daphne, Alabama. What is insulin resistance; What previous research on insulin resistance suggested; Results of the study.

  • Understanding insulin resistance and syndrome X. Garber, Alan J.; Gavin III, James R. // Patient Care;6/15/1996, Vol. 30 Issue 11, p198 

    Discusses insulin resistance in diabetic patients. Syndromes of insulin resistance; Treatment approaches; Consequences and complications. INSETS: The diabetes prevention program.;The patient with diabetes..

  • Management of syndrome X.  // American Family Physician;1/1/1997, Vol. 55 Issue 1, p341 

    Presents an abstract of an article in the November 1996 issue of the periodical `Canadian Family Physician,' that focused on the management of the insulin resistant condition called syndrome X. Manifestation of the disease; Factor attributed to the spread of syndrome X.

  • Erratum.  // Journal of Clinical Investigation;Mar2010, Vol. 120 Issue 3, p932 

    A correction to the article "Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure" is presented.

  • Leukemia drug available under treatment IND.  // FDA Consumer;Sep91, Vol. 25 Issue 7, p5 

    Reports that certain patients with an acute form of leukemia may now undergo treatment with a new bone marrow purging agent approved by the Food and Drug Administration (FDA) for wider experimental use. FDA authorized the expanded use of Pergamid(4-hydroperoxycylophosphamide, or 4-HC) June 14...

  • Vitamin A drug battles leukemia.  // Prevention;Aug93, Vol. 45 Issue 8, p27 

    States that doctors may soon use a drug derived from vitamin A to combat some types of leukemia. Tests of all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL); Report in the October 1992 issue of the `Australian and New Zealand Journal of Medicine'; More.

  • Leukemia drug approved.  // FDA Consumer;Jul/Aug91, Vol. 25 Issue 6, p2 

    Announces that the Food and Drug Administration has approved fludarabine, an `orphan' drug that offers people with the most common form of adult leukemia--chronic lymphocytic leukemia, or CLL--an improved quality of life and somewhat longer survival rates. Details on clinical trials; How drug...

  • Hairy cell leukemia treatment approved.  // FDA Consumer;Jan/Feb92, Vol. 26 Issue 1, p3 

    Reports that the drug Nipent (pentostatin) was approved Nov. 11, 1991, for treating patients seriously ill with hairy cell leukemia who do not respond to conventional treatment with alpha interferon. Details of the drug.

  • U.S. first to approve single-treatment cancer drug.  // FDA Consumer;May93, Vol. 27 Issue 4, p3 

    Informs that the United States is the first country to approve a single-treatment intravenous drug for hairy cell leukemia. Treatment regimen for Leustatin (cladribine); When the drug was approved by the Food and Drug Administration (FDA); Side effects; More.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics